The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets
The Oncology Institute (NASDAQ: TOI) announced a $110 million investment from Deerfield Management Company to accelerate its growth in the oncology market. The investment will involve issuing 4% secured senior convertible notes, maturing on August 9, 2027, which can be converted into approximately 12.84 million shares of common stock at an initial price of $8.567. This capital will expand TOI's patient access to high-quality, value-based care. The net proceeds are estimated at $106 million, aimed at funding acquisitions and general corporate purposes.
- Secured a $110 million investment to support growth.
- Proceeds will enhance access to high-quality, value-based cancer care.
- Convertible notes issued at a premium of 30% over closing stock price.
- Investment involves significant asset pledges and covenants.
Investment to accelerate Company’s expansion into new markets, bringing high-quality, value-based care to more patients
CERRITOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today announced entry into an agreement for the investment of
“We are very pleased to announce this strategic investment from Deerfield, one of the most active and experienced healthcare investors in the country.” said Brad Hively, CEO of TOI. “This investment will provide TOI with important growth capital to accelerate our expansion into new markets with our differentiated value-based approach to oncology. This represents a significant milestone in our journey to disrupt the >
TOI has agreed to issue Deerfield
The Convertible Notes may be redeemed by TOI at any time, in whole or in part, upon the payment of a
The Company estimates that the net proceeds from the sale of the Convertible Notes will be approximately
Guggenheim Securities, LLC is acting as lead financial advisor and Jefferies LLC is acting as lead placement agent to TOI. Latham & Watkins LLP is acting as legal advisor to TOI, and Katten Muchin Rosenman LLP is acting as legal advisor to Deerfield.
About The Oncology Institute, Inc.
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Media
The Oncology Institute
Julie Korinke
juliekorinke@theoncologyinstitute.com
(562) 735-3226 x 88806
Investors
Solebury Trout
Maria Lycouris
investors@theoncologyinstitute.com
FAQ
What is the significance of The Oncology Institute's $110 million investment?
What are the terms of the convertible notes issued by The Oncology Institute?
How will The Oncology Institute use the proceeds from the investment?
What is The Oncology Institute's market strategy following the Deerfield investment?